#USA #Orlando #Nordic Pharma #LACRIFILL #Dry Eye Gel

Introduction

Nordic Pharma, Inc., a well-established player in the pharmaceutical industry and a subsidiary of Nordic Group B.V., is set to make a significant mark at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting. Taking place from October 18 to 20 in Orlando, FL, the event will highlight their innovative LacriFill Canalicular Gel, a pioneering solution aimed at alleviating symptoms associated with dry eye disease. This year's presentation promises to bring new patient data and unique insights into patient experiences that underscore the efficacy and impact of this novel therapy.

Importance of LacriFill Canalicular Gel

The introduction of LacriFill Canalicular Gel into the market signifies a substantial advancement in the treatment of dry eye symptoms. During AAO 2025, Nordic Pharma aims to engage eye care professionals by presenting compelling evidence from recent studies—an impressive 98.11% of first-time and repeat patients expressed a strong willingness to return for further doses of LacriFill. Dr. Jai Parekh, Chief Commercial Officer of Eye Care U.S., emphasized the importance of this feedback: "The overwhelming response from patients demonstrates the positive impact LacriFill has, reinforcing our commitment to providing solutions that benefit both patients and healthcare providers."

Additionally, LacriFill incorporates a unique crosslinked hyaluronic acid formulation, designed to provide extended benefits for up to six months. This allows practitioners to optimize the ocular surface before cataract or refractive surgeries and maintain results in the postoperative phase.

Collaborative Contributions

The AAO meeting will also serve as a platform for distinguished professionals like Dr. Vance Thompson and Dr. Kayla Karpuk to share their findings through a forthcoming article in the Expert Review of Ophthalmology. This research specifically addresses the implications of ocular surface health on surgical outcomes, an increasingly vital aspect for patients undergoing surgery.

Dr. Thompson points out, "Utilizing LacriFill before surgery can enhance the surgical experience for patients suffering from dry eye disease, ensuring better outcomes and improved satisfaction levels post-operation."

Engagement at AAO 2025

The networking opportunities at AAO are not to be missed. On October 18, Nordic Pharma continues its tradition of supporting women's achievements in ophthalmology by sponsoring the Women in Ophthalmology (WIO) Awards Ceremony Networking Reception. This event is a testament to Nordic Pharma's dedication to fostering an inclusive environment within the field and recognizing the invaluable contributions made by women ophthalmologists. CEO Lisa M. Nijm remarked, "We are incredibly grateful for Nordic Pharma's ongoing partnership in celebrating remarkable women who greatly influence our industry."

AAO attendees are encouraged to visit Nordic Pharma's booth (#1401) for informative sessions showcasing injection demonstrations of LacriFill, providing hands-on experience with this innovative treatment.

Contributions to the Research Community

The new TFOS Dry Eye Workshop (DEWS) III report has recently spotlighted two important studies on LacriFill published in the American Journal of Ophthalmology. These studies corroborate the effectiveness and safety of LacriFill compared to traditional methods, with statistically significant improvements noted in signs and symptoms up to six months post-treatment.

Such findings reflect Nordic Pharma's commitment to advancing the knowledge base in ophthalmology while also reasserting its position as a leader in innovative dry eye treatments.

Closing Thoughts

As Nordic Pharma approaches AAO 2025, the spotlight on LacriFill Canalicular Gel underlines its potential to transform patient care within ophthalmology. Data from numerous studies not only support its use but reinforce its necessity in the ongoing battle against dry eye disease. The results presented at AAO will further enhance the critical conversation regarding innovative therapies in eye care and their role in improving patient outcomes. Interested parties can find more information about LacriFill Canalicular Gel at lacrifill.com, where they can also place orders for this groundbreaking product.

Through focused engagements and meaningful discussions, Nordic Pharma looks forward to shaping the future of ophthalmic care at AAO 2025.